Bright Minds Biosciences (DRUG) Competitors $25.74 +2.48 (+10.64%) As of 09:32 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DRUG vs. IMNM, GYRE, PHAT, VIR, CRON, REPL, PHAR, XERS, TRVI, and IMTXShould you be buying Bright Minds Biosciences stock or one of its competitors? The main competitors of Bright Minds Biosciences include Immunome (IMNM), Gyre Therapeutics (GYRE), Phathom Pharmaceuticals (PHAT), Vir Biotechnology (VIR), Cronos Group (CRON), Replimune Group (REPL), Pharming Group (PHAR), Xeris Biopharma (XERS), Trevi Therapeutics (TRVI), and Immatics (IMTX). These companies are all part of the "pharmaceutical products" industry. Bright Minds Biosciences vs. Its Competitors Immunome Gyre Therapeutics Phathom Pharmaceuticals Vir Biotechnology Cronos Group Replimune Group Pharming Group Xeris Biopharma Trevi Therapeutics Immatics Bright Minds Biosciences (NASDAQ:DRUG) and Immunome (NASDAQ:IMNM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends. Which has higher valuation & earnings, DRUG or IMNM? Bright Minds Biosciences has higher earnings, but lower revenue than Immunome. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBright Minds BiosciencesN/AN/A-$2.06M-$0.36-71.51Immunome$9.04M88.41-$292.96M-$3.18-2.89 Do analysts prefer DRUG or IMNM? Bright Minds Biosciences currently has a consensus target price of $83.25, suggesting a potential upside of 223.36%. Immunome has a consensus target price of $23.33, suggesting a potential upside of 154.04%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Bright Minds Biosciences is more favorable than Immunome.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bright Minds Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Immunome 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, DRUG or IMNM? Bright Minds Biosciences has a beta of -5.74, meaning that its stock price is 674% less volatile than the S&P 500. Comparatively, Immunome has a beta of 1.94, meaning that its stock price is 94% more volatile than the S&P 500. Do institutionals & insiders hold more shares of DRUG or IMNM? 40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by company insiders. Comparatively, 8.6% of Immunome shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is DRUG or IMNM more profitable? Bright Minds Biosciences has a net margin of 0.00% compared to Immunome's net margin of -1,875.21%. Bright Minds Biosciences' return on equity of -14.56% beat Immunome's return on equity.Company Net Margins Return on Equity Return on Assets Bright Minds BiosciencesN/A -14.56% -14.29% Immunome -1,875.21%-71.65%-60.36% Does the media favor DRUG or IMNM? In the previous week, Bright Minds Biosciences had 1 more articles in the media than Immunome. MarketBeat recorded 3 mentions for Bright Minds Biosciences and 2 mentions for Immunome. Bright Minds Biosciences' average media sentiment score of 1.21 beat Immunome's score of 0.88 indicating that Bright Minds Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bright Minds Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunome 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryBright Minds Biosciences beats Immunome on 11 of the 15 factors compared between the two stocks. Get Bright Minds Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DRUG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRUG vs. The Competition Export to ExcelMetricBright Minds BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$163.91M$2.84B$5.45B$8.90BDividend YieldN/A2.70%5.36%4.14%P/E Ratio-71.5121.1526.4219.67Price / SalesN/A261.71406.85110.35Price / CashN/A41.2925.8827.49Price / Book27.987.247.915.42Net Income-$2.06M-$55.05M$3.15B$248.34M7 Day Performance-8.05%-1.01%0.62%0.81%1 Month Performance-0.98%5.98%4.94%5.01%1 Year Performance2,351.67%0.83%32.26%18.10% Bright Minds Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRUGBright Minds Biosciences3.1994 of 5 stars$25.75+10.6%$83.25+223.4%+2,307.3%$163.91MN/A-71.51N/APositive NewsGap UpIMNMImmunome2.232 of 5 stars$8.74-0.1%$23.33+167.0%-23.1%$761.36M$10.94M-2.7540GYREGyre Therapeutics0.3129 of 5 stars$7.77-3.7%N/A-38.4%$756.62M$105.76M388.6940PHATPhathom Pharmaceuticals3.7258 of 5 stars$9.47-9.1%$17.50+84.8%-6.9%$727.46M$55.25M-1.81110High Trading VolumeVIRVir Biotechnology3.4032 of 5 stars$5.05-3.4%$32.86+550.6%-43.4%$722.98M$74.21M-1.20580News CoveragePositive NewsCRONCronos Group2.2342 of 5 stars$1.87+0.5%N/A-18.0%$717.37M$117.61M14.39450REPLReplimune Group3.9763 of 5 stars$9.23-0.4%$20.83+125.7%+3.2%$714.59MN/A-3.01210PHARPharming Group3.1443 of 5 stars$10.49+0.3%$30.00+186.1%+27.9%$710.92M$297.20M-52.42280Positive NewsGap DownXERSXeris Biopharma4.1705 of 5 stars$4.64+2.9%$6.25+34.7%+107.6%$705.29M$203.07M-15.47290Positive NewsTRVITrevi Therapeutics2.0721 of 5 stars$5.75-3.5%$20.29+252.8%+83.6%$699.07MN/A-12.7820Analyst ForecastIMTXImmatics3.0596 of 5 stars$5.42-3.4%$14.67+170.6%-53.7%$681.90M$168.65M-31.88260 Related Companies and Tools Related Companies Immunome Competitors Gyre Therapeutics Competitors Phathom Pharmaceuticals Competitors Vir Biotechnology Competitors Cronos Group Competitors Replimune Group Competitors Pharming Group Competitors Xeris Biopharma Competitors Trevi Therapeutics Competitors Immatics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRUG) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredNvidia’s Huang: AI is going to need 100x more power12Nvidia CEO Jensen Huang didn't mince words. After Nvidia's latest earnings call, Huang said AI now requires...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bright Minds Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bright Minds Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DRUG Stock Alerts